Blair Jobe MD
A research team led by Allegheny Health Network surgical oncologist Blair Jobe, MD, has developed and validated a four-protein serum biomarker panel that holds significant promise for early detection of esophageal cancer, a relatively rare but often deadly disease that has grown in incidence over the past several decades.
findings were published online today in Cancer, a journal of the American Cancer Society
The four-protein panel, called B-AMP (biglycan, myeloperoxidase, annexin-A6 and protein S100-A9), is a simple, non-invasive, low-cost blood test, that identified esophageal cancer with a high classification accuracy of 87 percent in the study.
The discovery represents a major step forward in not only early detection but also the management of esophageal cancer, said Dr. Jobe, Director of Allegheny Health Network's Esophageal and Thoracic Institute.
The test is already being used at the Institute in a clinical trial setting to monitor the course of esophageal cancer, providing physicians with guidance on response to therapy or early notification of a recurrence and allowing them to pursue different or more aggressive therapies, if necessary.
"Esophageal cancer patients often have few options available to fight this disease, and five-year survival rates are extremely low at about 15 percent," said Dr. Jobe
Followed by novel mathematical modeling, Dr. Jobe's
team was able to combine relevant and strong individual biomarkers into a panel that is accurate and reliable in detecting esophageal cancer.
"Dr. Jobe's research shows the value of our approach to working collaboratively and across the full spectrum of disease," said David Parda, MD, System Chair, Allegheny Health Network Cancer Institute.